Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지

Sequential Chemoradiotherapy for Stage I/II Nasal Natural Killer/T Cell Lymphoma

I/II 병기 비강 Natural Killer/T Cell 림프종에 대한 순차적 항암화학요법과 방사선치료

  • Noh Young Joo (Department of Radiation Oncology, Ulsan University Hospital , University of Ulsan College on Medicine) ;
  • Ahn Yong Chan (Departments of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim Won Seog (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Ko Young Hyeh (Department of Diagnostic Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 노영주 (울산대학교 의과대학 울산의대부속병원 방사선종양학과) ;
  • 안용찬 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 김원석 (성균관대학교 의과대학 삼성서울병원 내과) ;
  • 고영혜 (성균관대학교 의과대학 삼성서울병원 진단병리과)
  • Published : 2004.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Authors would report the results of sequential CHOP chemotherapy (cyclophosphamide, adriamycin, vincristine, and prednisone) and involved field radiotherapy (IFRT) for early stage nasal natural killer/T-cell Iymphoma (NKTCL). Materials and Methods: Fourteen among 17 patients, who were registered at the Samsung Medical Center tumor registry with stage I and II nasal NKTCL from March 1995 to December 1999 received this treatment protocol. Three to four cycles of CHOP chemotherapy were given at 3 weeks' interval, which was followed by local IFRT including the known tumor extent and the adjacent draining lymphatics. Results: Favorable responses after chemotherapy (before IFRT) were achievable only in seven patients (5 CR's+2 PR's: 50%), while seven patients showed disease progression. There were six patients with local failures, two with distant relapses, and none with regional lymphatic failure. The actuarial overall survival and progression-free survival at 3 years were 50.0% and 42.9%. All the failures and deaths occurred within 13 months of the treatment start. The factors that correlated with the improved survival were the absence of 'B' symptoms, the favorable response to chemotherapy and overall treatment, and the low risk by international prognostic index on univariate analyses. Conclusion: Compared with the historic treatment results by IFRT either alone or followed by chemotherapy, the current trial failed to demonstrate advantages with respect to the failure pattern and survival. Development of new treatment strategy in combining IFRT and chemotherapy is required for improving outcomes.

목적: 초기 병기 비강 natural killer/T-ceil 림프종에 대한 CHOP 항암화학요법과 국소 방사선치료의 순차적 적용 결과를 보고하고자 한다. 대상 및 방법: 1995년 3월부터 1999년 12월 사이에 성균관의대 삼성서울병원 종양센타에 비강 I/II 병기natural killer/T-cell 림프종으로 등록된 17명의 환자들 중 14명의 환자들에 대하여 순차적 항암화학요법과 방사선치료를 적용하였고 이들에 대한 분석을 시행하였다. 치료방침은 우선 CHOP 항암화학요법을 3주 간격으로 3~4회 시행한 후 5주간에 걸쳐 육안적 병변과 인접한 림프절 부위에 대한 국소 방사선치료를 추가하는 것이었다. 결과: 방사선치료의 시작 전에 시행한 국소종양의 항암화학요법에 대한 반응평가는 50%의 환자들에서 양호한 반응(완전관해 5명+부분관해 2명)을 보였고 나머지 50%의 환자들에서는 병변이 진행하였다. 5명의 환자에서 국소재발이 나타났는데 이들 중 2명은 원격전이를 동반하였고, 영역 림프절 재발을 수반한 경우는 없었다. 3년 생존율과 무병생존율은 50.0%와 42.9%였으며, 모든 사망과 재발사례는 치료개시 후 13개월 이내에 발생하였다. 예후인자의 단변량 분석에서 'B' 증상이 없는 경우, 항암화학요법과 전체 치료방침에 양호한 반응을 보인 경우, 국제예후지표상 저위험군 등이 양호한 생존율과 관련이 있었다. 결론: 본 연구의 치료방침에 의한 결과는 과거의 방사선치료 단독 또는 방사선치료 후 항암화학요법 추가에 따르는 결과들과 비교해 볼 때 재발양상과 생존율의 측면에서 유리한 점이 없었다. 따라서 방사선치료와 항암화학요법을 새로운 병용방법에 관한 연구개발이 요망된다.

Keywords

References

  1. Davison SP, Habermann TM, Strickler JG, DeRemee RA, Earle JD, McDonald TJ. Nasal and nasopharyngeal angiocentric T-cell lymphomas. Laryngoscope 1996;106:139-143 https://doi.org/10.1097/00005537-199602000-00005
  2. Kim GE, Cho JH, Yang WI, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol 2000;18:54-63
  3. Smalley SR, Cupps RE, Anderson JA, et al. Polymorphic reticulosis limited to the upper aerodigestive tract-natural history and radiotherapeutic considerations. Int J Radiat Oncol Biol Phys 1988;15:599-605 https://doi.org/10.1016/0360-3016(88)90300-8
  4. Kim JS, Ahn YC, Yun HG, Park CI. Primary Radiation Therapy of Polymorphic Reticulosis. J Korean Soc Therapeut Radiol Oncol 1991;9(1):111-116
  5. Kaminski MS, Coleman CN, Colby TV, Cox RS, Rosenberg SA. Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med 1986;104:747-756 https://doi.org/10.7326/0003-4819-104-6-747
  6. Mauch P, Leonard R, Skarin A, et al. Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non- Hodgkin's lymphomas. J Clin Oncol 1985;3:1301-1308 https://doi.org/10.1200/JCO.1985.3.10.1301
  7. Monfardini S, Banfi A, Bonadonna G, et al. Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 1980;6:125-134 https://doi.org/10.1016/0360-3016(80)90027-9
  8. Nissen NI, Ersboll J, Hansen HS, et al. A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas. Cancer 1983;52:1-7 https://doi.org/10.1002/1097-0142(19830701)52:1<1::AID-CNCR2820520102>3.0.CO;2-M
  9. Aozasa K, Ohsawa M, Tajima K, et al. Nation-wide study of lethal midline granuloma in Japan: frequencies of Wegener's granulomatosis, polymorphic reticulosis, malignant lymphoma and other related conditions. Int J Cancer 1989;44:63-66 https://doi.org/10.1002/ijc.2910440112
  10. Campo E, Cardesa A, Alos L, et al. Non-Hodgkin's lymphomas of nasal cavity and paranasal sinuses. An immunohistochemical study. Am J Clin Pathol 1991;96:184-190 https://doi.org/10.1093/ajcp/96.2.184
  11. Fellbaum C, Hansmann ML, Lennert K. Malignant lymphomas of the nasal cavity and paranasal sinuses. Pathol Anat Histopathol 1989;414:399-405 https://doi.org/10.1007/BF00718623
  12. Ho FC, Choy D, Loke SL, et al. Polymorphic reticulosis and conventional lymphomas of the nose and upper aerodigestive tract: a clinicopathologic study of 70 cases, and immunophenotypic studies of 16 cases. Hum Pathol 1990;21:1041-1050 https://doi.org/10.1016/0046-8177(90)90254-3
  13. Ng CS, Chan JK, Lo ST, Poon YF. Immunophenotypic analysis of non-Hodgkin's lymphomas in Chinese. A study of 75 cases in Hong Kong. Pathology 1986;18:419-425 https://doi.org/10.3109/00313028609087562
  14. Wong DS, Fuller LM, Butler JJ, Shullenberger CC. Extranodal non-Hodgkin's lymphomas of the head and neck. Am J Roen Radium Ther Nucl Med 1975;123:471-481 https://doi.org/10.2214/ajr.123.3.471
  15. Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997;89:4501-4513
  16. van Gorp J, Weiping L, Jacobse K, et al. Epstein-Barr virus in nasal T-cell lymphomas (polymorphic reticulosis/midline malignant reticulosis) in estern China. J Pathol 1994;173:81-87 https://doi.org/10.1002/path.1711730203
  17. Eichel BS, Harrison EG Jr, Devine KD, Scanlon PW, Brown HA. Primary lymphoma of the nose including a relationship to lethal midline granuloma. Am J Surg 1966;112:597-605 https://doi.org/10.1016/0002-9610(66)90328-X
  18. Tsai TF, Su IJ, Lu YC, et al. Cutaneous angiocentric T-cell lymphoma associated with Epstein-Barr virus. J Am Acad Dermatol 1992;26:31-38 https://doi.org/10.1016/0190-9622(92)70002-W
  19. Wong KF, Chan JK, Ng CS, Lee KC, Tsang WY, Cheung MM. CD56 (NKH1)-positive hematolymphoid malignancies: an aggressive neoplasm featuring frequent cutaneous/ mucosal involvement, cytoplasmic azurophilic granules, and angiocentricity. Hum Pathol 1992;23:798-804 https://doi.org/10.1016/0046-8177(92)90350-C
  20. Jaffe ES, Krenacs L, Kumar S, Kingma DW, Raffeld M. Extranodal peripheral T-cell and NK-cell neoplasms. Am J Clin Pathol 1999;111:S46-S55
  21. Chan JK, Tsang WY, Pau MY. Discordant CD3 expression in lymphomas when studied on frozen and paraffin sections. Hum Pathol 1995;26:1139-1143 https://doi.org/10.1016/0046-8177(95)90277-5
  22. Jaffe ES. Classification of natural killer (NK) cell and NK-like T cell malignancies. Blood 1996;87:1207-1210
  23. Ng CS, Chan JK, Lo ST. Expression of natural killer cell markers in non-Hodgkin's lymphomas. Hum Pathol 1987;18:1257-1262 https://doi.org/10.1016/S0046-8177(87)80410-0
  24. Ohsawa M, Nakatsuka S, Kanno H, et al. Immunophenotypic and genotypic characterization of nasal lymphoma with polymorphic reticulosis morphology. Int J Cancer 1999;81:865-870 https://doi.org/10.1002/(SICI)1097-0215(19990611)81:6<865::AID-IJC5>3.0.CO;2-S
  25. Harris NL. Principles of the revised European-American Lymphoma Classification (from the International Lymphoma Study Group). Ann Oncol 1997;8(S2):11-16
  26. Chan JK, Tsang WY, Hui PK, et al. T-and T/natural killer-cell lymphomas of the salivary gland: a clinicopathologic, immunohistochemical and molecular study of six cases. Hum Pathol 1997;28:238-245 https://doi.org/10.1016/S0046-8177(97)90113-1
  27. Chan JK, Tsang WY, Lau WH, et al. Aggressive T/natural killer cell lymphoma presenting as testicular tumor. Cancer 1996;77:1198-1205 https://doi.org/10.1002/(SICI)1097-0142(19960315)77:6<1198::AID-CNCR29>3.0.CO;2-W
  28. Jaffe ES, Chan JK, Su IJ, et al. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20:103-111 https://doi.org/10.1097/00000478-199601000-00012
  29. Nakamura S, Suchi T, Koshikawa T, et al. Clinicopathologic study of CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract. Am J Surg Pathol 1995;19:284-296 https://doi.org/10.1097/00000478-199503000-00006
  30. Shneider B, Touloukian R, Hajjar F, Selsky C, Buckley P. Perianal ulceration. A novel manifestation of angiocentric lymphoma. Dig Dis Sci 1993;38:1162-1166 https://doi.org/10.1007/BF01295737
  31. Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HS. World Health Organization classification of neoplastic disease of the hematopoietic and lymphoid Tissues. A progress report. Am J Clin Pathol 1999;111(S1):S8-12
  32. Halperin EC, Dosoretz DE, Goodman M, Wang CC. Radiotherapy of polymorphic reticulosis. Br J Radiol 1982;55:645-649 https://doi.org/10.1259/0007-1285-55-657-645
  33. Itami J, Itami M, Mikata A, et al. Non-Hodgkin's lymphoma confined to the nasal cavity: its relationship to the polymorphic reticulosis and results of radiation therapy. Int J Radiat Oncol Biol Phys 1991;20:797-802 https://doi.org/10.1016/0360-3016(91)90026-Z
  34. Tao Q, Ho FC, Loke SL, Srivastava G. Epstein-Barr virus is localized in the tumour cells of nasal lymphomas of NK, T or B cell type. Int J Cancer 1995;60:315-320 https://doi.org/10.1002/ijc.2910600306
  35. Sobrevilla-Calvo P, Meneses A, Alfaro P, Bares JP, Amador J, Reynoso EE. Radiotherapy compared to chemotherapy as initial treatment of angiocentric centrofacial lymphoma (polymorphic reticulosis). Acta Oncol 1993;32:69-72 https://doi.org/10.3109/02841869309083888
  36. Cheung MM, Chan JK, Lau WH, et al. Primary non- Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998;16:70-77 https://doi.org/10.1200/JCO.1998.16.1.70
  37. Li YX, Coucke PA, Li JY, et al. Primary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer 1998;83:449-456 https://doi.org/10.1002/(SICI)1097-0142(19980801)83:3<449::AID-CNCR13>3.0.CO;2-W
  38. Liang R, Todd D, Chan TK, et al. Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol 1995;13:666-670 https://doi.org/10.1200/JCO.1995.13.3.666
  39. Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995;76:2351-2356 https://doi.org/10.1002/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1